Denali Therapeutics Inc. DNLI R2K

Healthcare · Biotechnology · United States

https://www.denalitherapeutics.com

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Market & Price

Market Cap

$3.34B

Current Price

$21.04

High / Low (52W)

$22.74 / $12.75

Beta

0.99

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$5.84

Price to Book

3.60

P/S

EV/EBITDA

-4.50

Dividend Yield

Profitability & Returns

ROCE

-53.07%

ROE

-49.59%

ROA

-26.95%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.69

EPS (TTM)

$-2.88

Balance Sheet & Liquidity

Debt/Equity

4.32

Quick Ratio

8.98

Current Ratio

9.29

Debt

$40.05M

Total Assets

$1.14B

Current Assets

$900.66M

Working Capital

$802.31M

Ownership

Promoter Holding

9.13%

Chg in Prom Hold

FII / Inst Holding

99.58%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$2.39B

Total Revenue (TTM)

EBITDA

$-531.76M

Free Cash Flow

$-190.33M

Operating Cash Flow

$-412.34M

Shares Outstanding

158.71M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-33.33%

Profit 5Y

-19.08%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -33.3% CAGR over 5 years.
Earnings shrank at -19.1% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	DNLI Denali Therapeutics Inc. R2K	21.04	-	$3.34B	-	-53.07%	-49.59%	-33.33%	-19.08%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	0	0	-	641.00K	1.65M	1.20M	125.68M	4.11M	4.10M	13.51M	4.67M	3.55M	5.81M	9.39M	7.92M	22.94M	5.29M	42.14M	52.48M	184.00K	35.14M	294.12M	1.27M	0	0	0	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145.58M	134.96M	137.43M	137.37M	137.36M
Operating Income	-21.74M	-22.57M	-22.29M	-23.54M	-25.75M	-57.38M	-37.96M	74.72M	-42.51M	-62.76M	-50.16M	-57.76M	-59.97M	-61.28M	-60.12M	-71.22M	-61.82M	-85.59M	-66.50M	-61.42M	-107.49M	-120.81M	170.48M	-113.80M	-117.72M	-116.59M	-123.19M	-	-145.58M	-134.96M	-137.43M	-137.37M	-137.36M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-142.37M	-131.01M	-133.57M	-133.58M	-133.60M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-132.97M	-124.12M	-126.90M	-128.45M	-128.45M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-21.32M	-22.13M	-21.84M	-22.89M	-23.68M	-54.72M	-35.37M	77.53M	-38.99M	-58.34M	-46.26M	-54.02M	-56.76M	-58.76M	-58.23M	-70.04M	-60.69M	-84.59M	-65.22M	-58.79M	-103.30M	-109.78M	183.38M	-99.35M	-101.80M	-99.03M	-107.19M	-	-132.97M	-124.12M	-126.90M	-128.55M	-128.45M
Diluted EPS	-	-	-	-	-0.26	-0.59	-0.38	0.79	-	-	-	-	-0.55	-0.56	-0.54	-0.58	-0.50	-0.69	-0.53	-0.48	-0.84	-0.80	1.30	-0.72	-0.68	-0.59	-0.63	-	-0.78	-0.72	-0.74	-0.73	-0.69
R&D Expense	18.47M	19.00M	18.52M	-	20.82M	52.13M	30.32M	-	37.40M	51.88M	52.54M	-	51.02M	53.15M	53.70M	60.21M	65.71M	71.56M	86.10M	92.74M	87.79M	128.82M	97.52M	89.74M	107.02M	91.40M	98.24M	-	116.23M	102.70M	101.95M	-	103.85M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	129.10M	26.32M	335.56M	-	108.46M	330.53M	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	449.21M	527.23M	501.88M	555.34M
Operating Income	-87.43M	-90.14M	-46.37M	-213.18M	62.72M	-	-340.74M	-196.70M	-501.88M	-555.34M
EBITDA	-	-	-	-	-	-	-330.36M	-179.97M	-492.89M	-540.53M
Interest Expense	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-325.97M	-145.19M	-422.70M	-512.44M
Tax Provision	-	-	-	-	-	-	21.00K	30.00K	68.00K	102.00K
Net Income	-86.65M	-88.19M	-36.24M	-197.61M	71.14M	-	-325.99M	-145.22M	-422.77M	-512.54M
Diluted EPS	-	-	-0.39	-2.07	0.63	-2.39	-2.60	-1.06	-2.57	-
R&D Expense	75.70M	74.46M	143.18M	193.38M	212.62M	265.35M	358.73M	423.88M	396.44M	418.78M

Compounded Sales Growth

5 Years:	-33.33%
1 Year:	-

Compounded Profit Growth

5 Years:	-19.08%
1 Year:	-

Stock Price Performance

1 Year:	+58.91%
6 Months:	+9.98%
3 Months:	-0.66%
1 Month:	+13.12%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	486.72M	661.98M	553.23M	1.60B	-	1.46B	1.15B	1.37B	1.14B
Current Assets	-	-	-	-	-	-	-	1.37B	1.06B	864.44M	900.66M
Cash & Equivalents	-	39.85M	218.38M	77.12M	79.45M	507.14M	-	218.04M	127.11M	174.96M	205.33M
Inventory	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	9.28M	3.42M	2.17M	2.18M
Total Liabilities	-	-	20.93M	115.14M	158.34M	453.75M	-	417.81M	122.96M	144.50M	131.09M
Current Liabilities	-	-	14.16M	32.79M	45.34M	71.70M	-	363.92M	77.98M	102.21M	98.35M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	60.35M	52.24M	48.71M	36.76M
Total Equity	-15.63M	-94.15M	465.80M	546.85M	394.89M	1.15B	-	1.04B	1.03B	1.23B	1.01B
Shares Outstanding	-	-	-	-	-	-	-	135.97M	138.39M	144.22M	156.18M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-71.91M	-76.64M	50.12M	-151.58M	416.15M	-211.39M	-244.72M	-357.99M	-347.69M	-412.60M
Investing Cash Flow	-219.00M	-41.17M	-287.42M	147.71M	-623.21M	-21.63M	-141.39M	249.31M	-88.76M	255.28M
Financing Cash Flow	300.48M	296.32M	97.02M	6.19M	634.75M	19.35M	310.67M	17.82M	484.30M	189.22M
Capital Expenditure	-6.13M	-2.88M	-3.39M	-17.92M	-3.10M	-8.50M	-17.83M	-12.94M	-15.91M	-9.50M
Free Cash Flow	-78.04M	-79.51M	46.72M	-169.50M	413.06M	-219.89M	-262.55M	-370.93M	-363.61M	-422.10M
Net Change in Cash	-	-	-	-	-	-	-75.43M	-90.86M	47.85M	31.90M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-35.9%	-810.0%	18.7%	-	-314.2%	-59.5%	-	-
Net Margin %	-	-	-28.1%	-750.8%	21.2%	-	-300.6%	-43.9%	-	-
ROE %	92.0%	-18.9%	-6.6%	-50.0%	6.2%	-	-31.3%	-14.1%	-34.4%	-50.6%
ROCE %	-	-19.1%	-7.4%	-42.0%	4.1%	-	-31.1%	-18.3%	-39.5%	-53.1%

Shareholding Pattern

Insiders

9.13%

Institutions

99.58%

Public Float

109.58%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.21%	13.03M	$274.24M
2	BAILLIE GIFFORD & CO	7.60%	12.07M	$253.88M
3	T. Rowe Price Investment Management, Inc.	5.37%	8.52M	$179.24M
4	Temasek Holdings (Private) Ltd	4.42%	7.01M	$147.55M
5	State Street Corporation	3.95%	6.27M	$131.96M
6	Vanguard Capital Management LLC	3.87%	6.15M	$129.35M
7	Vanguard Portfolio Management LLC	3.86%	6.12M	$128.77M
8	FMR, LLC	2.88%	4.58M	$96.27M
9	UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	2.79%	4.43M	$93.26M
10	Goldman Sachs Group Inc	2.78%	4.41M	$92.73M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DNLI

No recent headlines available.

DNLI · Healthcare